In 2020, by constructing long-term (greater than 3 months, more than 10 generations), and short-term (less than 3 months, less than 10 generations) NSCLC organoid models, Shi found that cancer organoids with breast cancer 2 gene, EGFR, and EGFR- and EGFR-mutation/MSC-epithelial-transformation (MET)-amplified mutations responded favourably to lapatinib, erlotinib, and crizotinib, respectively (Shi et al., 2020). This evidence concerns the gene EGFR and cancer.